Head-to-Head Comparison of ^{64}Cu-DOTATATE and ^{68}Ga-DOTATOC PET/CT: A Prospective Study of 59 Patients with Neuroendocrine Tumors

Camilla B. Johnbeck[1,2], Ulrich Knigge[2,3], Annika Loft[1,2], Anne K. Berthelsen[1,2], Jann Mortensen[1,2], Peter Oturai[1,2], Seppo W. Langer[2,4], Dennis R. Elema[5], and Andreas Kjaer[1,2]

[1]Department of Clinical Physiology, Nuclear Medicine, and PET and Cluster for Molecular Imaging, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark; [2]ENETS Neuroendocrine Tumor Center of Excellence, Rigshospitalet, Copenhagen, Denmark; [3]Department of Surgical Gastroenterology and Department of Clinical Endocrinology, Rigshospitalet, Copenhagen, Denmark; [4]Department of Oncology, Rigshospitalet, Copenhagen, Denmark; and [5]Hevesy Laboratory, DTU Nutech, Technical University of Denmark, Roskilde, Denmark

Somatostatin receptor imaging is a valuable tool in the diagnosis, follow-up, and treatment planning of neuroendocrine tumor (NET). PET-based tracers using ^{68}Ga as the radioisotope have in most centers replaced SPECT-based tracers as the gold standard. ^{64}Cu-DOTATATE is a new PET tracer that has been shown to be far superior to the SPECT tracer ^{111}In-diethylenetriaminepentaacetic acid-octreotide. Because of the advantages of ^{64}Cu over ^{68}Ga, we hypothesized that the tracer has a higher sensitivity than ^{68}Ga-based tracers. To test this hypothesis, we compared on a head-to-head basis the diagnostic performance of ^{64}Cu-DOTATATE with that of ^{68}Ga-DOTATOC in NET patients. **Methods:** Fifty-nine NET patients were scanned with both ^{64}Cu-DOTATATE and ^{68}Ga-DOTATOC PET/CT and compared on a head-to-head basis. Discordant lesions were verified during at least 30 mo of follow-up. **Results:** A total of 701 lesions were concordantly detected on both ^{64}Cu-DOTATATE and ^{68}Ga-DOTATOC PET/CT scans, whereas an additional 68 lesions were found by only one of the scans. ^{64}Cu-DOTATATE showed 42 lesions not found on ^{68}Ga-DOTATOC, of which 33 were found to be true-positive on follow-up. ^{68}Ga-DOTATOC showed 26 lesions not found on ^{64}Cu-DOTATATE, of which 7 were found to be true-positive on follow-up. False-positives were mainly lymph node lesions. Accordingly, 83% of the additional true lesions found on only one of the scans were found by ^{64}Cu-DOTATATE. On a patient-basis, additional true lesions were found by ^{64}Cu-DOTATATE and ^{68}Ga-DOTATOC in 13 and 3 patients, respectively. All patients with additional lesions also had concordant lesions found by both scans. **Conclusion:** ^{64}Cu-DOTATATE has advantages over ^{68}Ga-DOTATOC in the detection of lesions in NET patients. Although patient-based sensitivity was the same for ^{64}Cu-DOTATATE and ^{68}Ga-DOTATOC in this cohort, significantly more lesions were detected by ^{64}Cu-DOTATATE. Furthermore, the shelf life of more than 24 h and the scanning window of at least 3 h make ^{64}Cu-DOTATATE favorable and easy to use in the clinical setting.

The diagnosis of neuroendocrine tumors (NETs) is a challenging process since the symptoms are highly variable and the tumors are often small and can arise in any part of the body.

On average, there is 5- to 7-y delay from first symptoms to diagnosis in patients with NETs (*1*), and by then, 20%–50% of the patients have developed metastatic disease (*2*). Therefore, to reduce unnecessary delay, there is a great need for an early diagnosis by a sensitive and easy accessible diagnostic imaging method. Furthermore, sensitive imaging modalities are crucial in the long-term surveillance of NETs to detect possible progression at an early stage in order to rapidly change the treatment strategy.

One common feature of most NETs is the expression of abundant somatostatin receptors on the surface of tumor cells, which makes molecular imaging with radionuclide-coupled somatostatin analogs a strong diagnostic tool (*3*). Five subtypes of somatostatin receptor have been identified: sst1–sst5 (*4*). In NETs, mainly sst2 is expressed and to a lesser degree sst1 and sst5. It is less common to find sst3 and sst4 (*5–7*). Several radiotracers comprising a somatostatin analog chelated to a radioisotope have been developed for somatostatin receptor imaging. Even small modifications of the amino acid sequences, as well as the conjugation to a chelator and the choice of isotope, lead to changes in the affinity toward the different somatostatin receptors (*8,9*). Imaging of somatostatin receptors in NETs was initially achieved by γ-cameras using either planar or SPECT technique, and in most of North America this is still the case using ^{111}In-diethylenetriaminepentaacetic acid (DTPA)-octreotide.

The PET-based tracers, however, have major advantages over γ-emitting tracers, in terms of both detection rate and the quantitative nature (*9–14*). The Nordic guidelines state that PET is preferred over SPECT in the diagnostic work-up of NETs. In the European Neuroendocrine Tumor Society consensus guidelines, this recommendation of somatostatin receptor PET is supported mainly for low-proliferation gastroenteropancreatic tumors but also for

neuroendocrine carcinomas with a Ki-67 of below 55% and for low-grade lung NETs (15–19).

Many NET centers in Europe, including Copenhagen, have switched to PET-based imaging of NETs using mainly ^{68}Ga as the positron-emitting radioisotope coupled to different somatostatin analogs. The three most widely used are ^{68}Ga-DOTANOC, which has binding affinity mainly for sst2, sst3, and sst5; ^{68}Ga-DOTATOC, which has binding affinity mainly for sst2 and sst5; and ^{68}Ga-DOTATATE, which binds mainly to sst2 but with the highest affinity of all (3). The U.S. Food and Drug Administration approved ^{68}Ga-DOTATATE for diagnostic imaging of NETs in June 2016.

Recently, we introduced ^{64}Cu-DOTATATE as a new PET tracer for somatostatin receptor imaging. Compared with ^{111}In-DTPA-octreotide, it was superior in both radiation dose and lesion detection rates when tested on a head-to-head basis in 112 patients (14,20). The lower positron range of ^{64}Cu than of ^{68}Ga theoretically leads to a better spatial resolution, and the physical half-life of 12.7 h makes ^{64}Cu-DOTATATE attractive for routine use in a clinical imaging setting. In Copenhagen, the currently used tracer is ^{68}Ga-DOTATOC. The aim of the present study was therefore to compare, on a head-to-head basis, ^{64}Cu-DOTATATE with ^{68}Ga-DOTATOC, one of the PET tracers currently used most often for NETs. To determine whether discrepant lesions were true or false, clinical follow-up for 2 y as a minimum was undertaken.

MATERIALS AND METHODS

Study Design and Patients

Sixty patients, of whom 59 were evaluable, were prospectively enrolled in this study from the Departments of Clinical Endocrinology and Gastrointestinal Surgery in the Neuroendocrine Tumor Center of Excellence at Rigshospitalet, Copenhagen. All recruited patients were followed at the Center, and the inclusion criteria were primary staging or restaging. The study was approved by the Regional Scientific Ethical Committee (H-D-2008-045), and all participating patients signed an informed consent form. From June 2012 until March 2013, 60 patients underwent both ^{68}Ga-DOTATOC PET/CT and ^{64}Cu-DOTATATE PET/CT within 1 wk. Follow-up ended August 2015 for evaluation of whether discrepant lesions found by only one of the two PET tracers were true- or false-positive.

Synthesis and Radiolabeling of ^{64}Cu-DOTATOC and ^{68}Ga-DOTATATE

[64]Cu-DOTATATE was produced as previously described and approved under good manufacturing practice (20).

The ^{68}Ga-DOTATOC synthesis based on the acetone method was fully automated using a Modular Lab system (Eckert & Ziegler) and performed according to manufacturer instructions. Chemicals were obtained from Rotem. The radiochemical purity of ^{68}Ga-DOTATOC was more than 95%.

Image Acquisition

A 200-MBq injection of ^{64}Cu-DOTATATE was administered intravenously, and PET/CT was performed after 60 min. For the ^{68}Ga-DOTATOC scan, a 150-MBq injection was administered intravenously, and PET/CT was performed after 45 min. A Biograph 40 or 64 PET/CT scanner was used (Siemens Medical Systems). The same scanner was used for both patient scans. The CT component of the ^{64}Cu-DOTATATE PET/CT scan was of diagnostic quality and included intravenous contrast material; the other was low dose (120 kV; effective exposure, 40 mAs). Both PET/CT scans were performed within 1 wk of each other (1–5 d apart).

The PET scan was acquired in 3-dimensional list mode for 3 min per bed position, and the patients were positioned with arms above the head and scanned from forehead to midthigh. The PET reconstruction settings were CT-based attenuation correction, resolution recovery (point-spread function, TrueX algorithm [Siemens]), and time-of-flight technique (3 iterations, 21 subsets, zoom of 1.0). A gaussian filter of 2 mm in full width at half maximum was then applied to all images after reconstruction. The PET slice thickness was 2 mm.

Image Analysis

An experienced team with a nuclear medicine specialist and a radiologist evaluated the images in consensus. In all cases, foci were identified on the PET scan, and the CT scan was used mainly to confirm the anatomic location of PET foci. All lesions on the ^{64}Cu-DOTATATE and ^{68}Ga-DOTATOC scans were compared, and discordant additional lesions were noted for each of the scans.

Lesion sites were divided into regions or groups: liver, pancreas, intestines, lung, bones, lymph nodes, carcinomatosis, and other (ovaries, mamma, soft tissue, and other less common regions). The number of PET-positive lesions (≤ 20) in each region was counted, and the SUV_{max} of one concordant lesion in each region was noted. Furthermore, SUV_{max} was identified for several reference areas (liver, bone, lung, muscle, spleen, pancreas, intestine, and pituitary) in both scans. To compute tumor-to-background ratios (TBRs), background SUVs for organs (liver, lung, pancreas, bones, and intestines) were obtained from nondiseased areas within the same organ. The fifth vertebra was used as background for bone lesions when no SUV for reference bone was available in the same area. A muscle reference was used as background for lymph node TBR and, if no intestinal reference was available, also for carcinomatosis TBR. All TBRs of corresponding ^{64}Cu-DOTATATE and ^{68}Ga-DOTATOC scans were computed from the same background area on the two scans.

Clinical follow-up was more than 2 y. Discordant lesions were controlled by comparison to all available later images of the patients (^{68}Ga-DOTATOC PET/CT, CT, and MR) to verify the lesions as true- or false-positive findings.

Statistical Analysis

Dedicated statistical software was used for analysis (SPSS Statistics, version 22.0; IBM Corp.). For comparison of discrepant lesions using different PET tracers in the same patient, we applied the McNemar test for paired proportions corrected for continuity. The probability that a discordant observation was found by ^{64}Cu-DOTATATE was reported with the exact binomial confidence interval. The t test for paired samples was used to compare SUV_{max} for the two scans and to compare the TBRs.

RESULTS

One patient was omitted from the study at the quality check because the ^{68}Ga-DOTATOC had been subcutaneously injected. The characteristics of the remaining 59 patients are listed in Table 1. The ^{64}Cu-DOTATATE and ^{68}Ga-DOTATOC PET scans were compared at 3 levels (lesion-, region-, and patient-based). An overview of lesions and regions in patients with discordant scans is given in Table 2. The total number of lesions and the number of true-discordant lesions are listed in Table 3.

Lesions

In total, 701 PET-positive lesions were found by both tracers (concordant lesions), whereas an additional 68 lesions were found by only one tracer (discordant lesions).

For the 22 patients with divergent scans, all lesions found by the two tracers are listed in Table 2 according to tumor type, histology, region, and follow-up. ^{64}Cu-DOTATATE found 42 discordant lesions, and 33 of these were confirmed during follow-up to be true-positive.

TABLE 1
Characteristics of the 59 Patients

Characteristic	Data
Age at scanning (y)	
Mean	61
Range	32–81
Sex	
Male	35 (59%)
Female	24 (41%)
NET type	
Small intestinal	35 (59%)
Pancreatic	11 (19%)
Colonic	5 (9%)
Lung	2 (3%)
Other	3 (5%)
Unknown origin	3 (5%)
Classification	
GEP G1 (Ki-67 ≤ 2%)	12 (20%)
GEP G2 (Ki-67, 3%–20%)	40 (68%)
GEP G3 (Ki-67 > 20%)	0
Ki-67 not available	5 (9%)
Lung, typical carcinoid	1 (1.5%)
Atypical carcinoid	1 (1.5%)
Previous treatment	
Somatostatin analogs	32 (54%)
Surgery	32 (54%)
Interferon-α	27 (46%)
PRRT	19 (30%)
Chemotherapy	16 (27%)
Radiofrequency ablation	3 (5%)
Chemoembolization	3 (5%)

GEP = gastroenteropancreatic; PRRT = peptide receptor radionuclide therapy.

Data are *n* followed by percentage in parentheses, except for age.

A patient with a discordant bone lesion found only by ^{64}Cu-DOTATATE is seen in Figure 1. In this case, the true-positive nature of the finding was confirmed by positivity on a second ^{68}Ga-DOTATOC scan performed during follow-up 18 mo later. ^{68}Ga-DOTATOC found 26 discordant lesions, and 7 were confirmed to be true-positive (Table 2). Thus, ^{64}Cu-DOTATATE found significantly more true-positive discordant lesions than ^{68}Ga-DOTATOC (33 additional lesions vs. 7, $P < 0.001$). Of the true-positive discordant lesions, 83% were revealed by ^{64}Cu-DOTATATE but only 17% by ^{68}Ga-DOTATOC.

Regions

The additional true lesions found by ^{64}Cu-DOTATATE were located in bones, liver, lymph nodes, pancreas, or soft tissue or were carcinomatosis, whereas the additional true lesions found by ^{68}Ga-DOTATOC were located in liver, lymph nodes, and bone.

The probability that ^{64}Cu-DOTATATE would find a true-positive discordant lesion in bone was 85%. All discordant true-positive findings of carcinomatosis ($n = 7$) were detected by ^{64}Cu-DOTATATE. Most false-positive discordant foci (16/19) that were in both scans were located in lymph nodes and, to a lesser degree, in bone (Tables 2 and 3). There were significantly more false-positive discordant findings on ^{68}Ga-DOTATOC scans than on ^{64}Cu-DOTATATE scans (18/26 vs. 1/42).

Patients

Discrepant lesions between the ^{64}Cu-DOTATATE and ^{68}Ga-DOTATOC scans were found in a total of 22 patients (Table 2). Most additional lesions were found by ^{64}Cu-DOTATATE (in 14 patients), whereas ^{68}Ga-DOTATOC found additional lesions in 8 patients.

Follow-up confirmed that in 13 of 14 patients, ^{64}Cu-DOTATATE was true-positive for additional lesions, whereas a single PET-positive lymph node in the last patient (patient 30, Table 2) could not be verified.

In 3 of the 8 patients with additional lesions found by ^{68}Ga-DOTATOC, they were confirmed to be true-positive on follow-up. The additional lesions in the remaining 5 patients were not found on later imaging (^{68}Ga-DOTATOC, CT, or MR) and thus were considered false-positive. Altogether, significantly more patients (13 vs. 3) had additional true-positive lesions found by ^{64}Cu-DOTATATE ($P = 0.013$).

In 37 of the 59 patients, the ^{64}Cu-DOTATATE and ^{68}Ga-DOTATOC scans were concordant. The 2 lung NETs and 26 other NETs had multiple concordant lesions. In one of the patients, concordant positive lymph nodes turned out to be false-positive on follow-up, whereas the rest were considered true-positive. Nine patients showed no lesions on either of the scans, and they were confirmed to be true-negative on follow-up.

Although additional true lesions were found in 13 patients by ^{64}Cu-DOTATATE and in 3 patients by ^{68}Ga-DOTATOC, the sensitivity to diagnose NET disease in a patient was 100% (95% confidence interval [CI], 93%–100%), the specificity was 90% (95% CI, 56%–100%), the positive predictive value was 98% (95% CI, 90%–100%), and the negative predictive value was 100% (95% CI, 66%–100%) in both scans because concordant lesions were also found in all patients with additional lesions (Table 2). One example of such a patient is shown in Figure 2, where additional foci are seen in the intestinal region on the ^{64}Cu-DOTATATE scan. However, the diagnosis of primary intestinal tumor with widespread metastases was the same for both tracers.

Tracer Uptake

SUV_{max} was significantly higher for ^{64}Cu-DOTATATE than for ^{68}Ga-DOTATOC in liver lesions, lymph nodes, pancreatic lesions, intestinal tumors, and carcinomatosis lesions (Supplemental Table 1, available at http://jnm.snmjournals.org). Bone and lung did not significantly differ. The physiologic background uptake of the tracers was lower for ^{68}Ga-DOTATOC in all tissues except the spleen, where background uptake of ^{68}Ga-DOTATOC was significantly higher than that of ^{64}Cu-DOTATATE (Fig. 3; Supplemental Table 2).

The TBRs for the two tracers were compared within the 6 most typical regions—liver, lymph nodes, bone, lung, pancreas, and intestines—for ^{64}Cu-DOTATATE and ^{68}Ga-DOTATOC, and the results are shown in Table 4.

TABLE 2
Patients with Discordant Lesions on ^{64}Cu-DOTATATE or ^{68}Ga-DOTATOC PET

ID	Type	Ki-67	Concordant on both scans	Only on ^{64}Cu-DOTATATE (n = 42)	Only on ^{68}Ga-DOTATOC (n = 26)	Follow-up of discordant lesions (n = 68)	Imaging modality at follow-up	Months until follow-up
	Histology			Discordant				
3	Int	4%	Lung (1), pan (1), int (1), LN (6)	LN (3)		TP (3)	CT	17
5	Col	13%	Int (1), LN (4)	LN (1)		TP (1)	CT	24
8	Int	5%	Int (1), LN (1)	LN (1)		TP (1)	CT	20
9	Int	2%	Bone (5)		Bone (3)	TP (2), UV (1)	Ga	19
16	Int	2%	Liv (20), car (9), LN (8), bone (3), ov (2),	Car (3), LN (3), bone (1)		TP (1 LN), UV (6)	CT	14
17	Int	4%	Liv (1), int (1)		Liv (1)	TP (1)	MR	27
19	Int	3%	Int (1), LN (18)		LN (1)	FP (1)	Ga	25
21	Int		Int (3), liv (20), LN (8)		LN (12)	FP (12)	CT	26
29	Int	5%	Liv (6), LN (1)	Liv (1)		TP (1)	Ga	28
30	Pan	7%	Liv (20), pan (1), LN (4)	LN (1)		UV (1)	None	—
31	Int	2%	Lung (1), LN (19), bone (1)		LN (1)	FP (1)	Ga	22
35	Oth	15%	LN (10), bone (15)	Bone (5)		TP (5)	Ga	24
37	Int	2%	Liv (6), LN (5)	Liv (2)		TP (2)	Ga	7
43	Int	3%	Int (1), liv (10), car (1), LN (10), bone (8)		Bone (2)	FP (2)	Ga	6
44	Int	2%	Liv (7), LN (10)	Liv (1)		TP (1)	Ga	30
45	Int	2%	Liv (3), LN (4)		LN (1)	FP (1)	CT	0
49	Pan	6%	Pan (2)	Pan (1)		TP (1)	Ga	10
50	Int	10%	Int (1), liv (20), LN (5), bone (8),	Bone (5)		TP (5)	Ga	29
51	Int	5%	Int (1), liv (13), LN (17)		Liv (3), LN (2)	TP (4) FP (1 liv)	CT	4
56	Pan	10%	Liv (1)	Liv (3)		TP (3)	MR	13
57	Int	2%	Int (1), liv (10), LN (8), bone (6)	LN (1), bone (2)		TP (1 bone), UV (1), FP (1 LN)	Ga	29
59	Int	3%	LN (1), bone (3), car (3)	Car (7), ST (1)		TP (8)	Ga/CT	10/20

Car = carcinomatosis; col = colon; CT = high-dose CT; FP = false-positive; Ga = ^{68}Ga-DOTATOC PET with low-dose CT; ID = patient number; int = small intestinal; liv = liver; LN = lymph nodes; oth = other; ov = ovaries; pan = pancreas; ST = soft tissue; TP = true-positive; UV = unverified/uncertain.

The TBR for bones was significantly higher for ^{68}Ga-DOTATOC than for ^{64}Cu-DOTATATE. All other regions showed no significant differences.

DISCUSSION

Data on the diagnostic performance of ^{64}Cu-DOTATATE PET versus ^{111}In-DTPA-octreotide SPECT in NET patients were presented recently (14). Twice as many lesions were found by ^{64}Cu-DOTATATE, and additional organ involvement was detected in one third of the enrolled patients. There is no doubt that ^{64}Cu-DOTATATE should be preferred whenever possible over ^{111}In-DTPA-octreotide. However, most countries in Europe have changed their somatostatin receptor imaging of NETs to PET technology using ^{68}Ga-based tracers, and a similar trend applies in North America. Accordingly, the true challenge is how ^{64}Cu-DOTATATE performs in comparison with these widely used ^{68}Ga-based somatostatin receptor imaging tracers.

Both ^{64}Cu-DOTATATE and ^{68}Ga-DOTATOC were a priori expected to be highly sensitive. Accordingly, it was not surprising that on a patient basis there were no differences in the diagnostic performance of the two tracers. Nevertheless, significantly more additional true-positive lesions were revealed by ^{64}Cu-DOTATATE than by ^{68}Ga-DOTATOC: 33 versus 7.

It is a special characteristic of NET patients that they often live many years with widespread disease while receiving multiple treatments. Changes in treatment strategy are nearly always based on clinical or imaging-based signs of progression. Thus, a high performance in the detection of any new lesions is of great value in these patients. Additional lesions found by the ^{64}Cu-DOTATATE scan in the present study could not a priori be interpreted as a sign of progression since it was the first time this

TABLE 3
Comparison of Concordant and True-Positive Discordant Lesions Found by Concurrent ^{64}Cu-DOTATATE and
^{68}Ga-DOTATOC PET in the 59 Patients with NETs

Region	Concordant lesions	True-positive on ^{64}Cu-DOTATATE	True-positive on ^{68}Ga-DOTATOC	P	Probability that discordant lesion was found by ^{64}Cu-DOTATATE*
Liver	298	7	3	0.34	0.70 (0.67–0.93)
Lymph nodes	222	6	2	0.29	0.75 (0.35–0.98)
Bones	102	11	2	0.02	0.85 (0.55–0.98)
Lung	3	0	0	NA	NA
Pancreas	10	1	0	1.00	1.00 (0.05–1.00)
Intestines	26	0	0	NA	NA
Carcinomatosis	25	7	0	0.02	1.00 (0.59–1.00)
Other[†]	15	1*	0	1.00	1.00 (0.05–1.00)
Total	701	33	7	<0.001	0.83 (0.67–0.93)

*Data are estimate followed by 95% CI in parentheses.
[†]Breast (10), ovary (2), adrenal gland (1), soft tissue (3).
NA = not applicable.

new tracer had been used in these patients. Thus, the clinical impact of these additional findings could not be evaluated in the present study.

It could be argued that the difference found in our study was not due to use of a different isotope but rather to a difference in the peptide. Accordingly, the affinity (half-maximal inhibitory concentration) toward sst2 is approximately 10-fold higher for DOTATATE than for DOTATOC. Also, DOTATOC, in contrast to DOTATATE, has some affinity toward sst5 (8). However, in NETs, expression of sst2 receptors is much higher than that of any of the other subtypes (6). Accordingly, differences in non–sst2 receptor affinity are not expected to be of any importance. Also, the difference in sst2 receptor affinity seems clinically unimportant, as a recent review of PET tracers for somatostatin receptor imaging reported only marginal and inconsistent differences in diagnostic performance in NET patients between the 3 most frequently used ^{68}Ga-labeled somatostatin analogs: DOTATATE, DOTATOC and DOTANOC (3,21–27). In the only 2 studies that compared ^{68}Ga-DOTATATE and ^{68}Ga-DOTATOC head to head, by Poeppel et al., ^{68}Ga-DOTATOC showed the greatest number of lesions and the highest uptake in lesions (22,25). In contrast, a metaanalysis from 2014 found a higher patient-based sensitivity and specificity for ^{68}Ga-DOTATATE than for ^{68}Ga-DOTATOC (28). Thus, no consistent conclusion exists in which peptide is the most sensitive for overall NET imaging.

The difference in lesion detection rate found in the current study is presumed to relate to use of ^{64}Cu instead of ^{68}Ga rather than to differences in peptide. This finding was as expected, because the substantially shorter positron range of ^{64}Cu was anticipated to lead to better detection of small lesions.

The radiation burden is higher for ^{64}Cu-DOTATATE than for ^{68}Ga-DOTATOC, mainly because of the differences in positron-branching fraction. The positron-branching fraction is 0.17 for ^{64}Cu-DOTATATE and 0.89 for ^{68}Ga-DOTATOC, leading to the need to inject a higher dose of ^{64}Cu-DOTATATE to obtain the same number of counts as for ^{68}Ga-DOTATOC. However, the longer half-life of ^{64}Cu than of ^{68}Ga pulls in the opposite direction. Therefore,

only a 33% higher dose of ^{64}Cu-DOTATATE was used despite a nearly 5 times higher branching ratio for ^{68}Ga-DOTATOC. The higher radiation burden to the patient from ^{64}Cu-DOTATATE has to be considered. However, in our view this is not of any safety concern. Our typical ^{64}Cu-DOTATATE dose of 180–220 MBq results in a radiation dose of 5.7–8.9 mSv to the patient (20), whereas 120–200 MBq of ^{68}Ga-DOTATOC results in 2.8–4.6 mSv (29). For comparison, the radioactive burden from the γ-emitting tracers ^{111}In-DTPAOC and ^{111}In-DOTATOC, which are still used at many centers, is higher (5.7–11.1 mSv and 7.0–10.0 mSv, respectively) (30).


FIGURE 1. Initial PET/CT (left) and PET (right) scans show an additional bone lesion (arrow) with ^{64}Cu-DOTATATE. Follow-up with ^{68}Ga-DOTATOC confirms that finding was true-positive.

FIGURE 2. PET/CT (left) and PET (right) scans of patient with intestinal NET and multiple metastases. More lesions are seen in intestinal region with ⁶⁴Cu-DOTATATE than with ⁶⁸Ga-DOTATOC.

The TBR, or image contrast, did not significantly differ between the two tracers except in bone. Presumably, this finding is not a determinant for detection of bone lesions since


FIGURE 3. ⁶⁸Ga- and ⁶⁴Cu-DOTATATE PET/CT scans (color) and PET scans (black and white) of patient with intestinal NET and multiple metastases. Same 4 liver lesions are seen on transaxial images (left), and same 2 bone lesions are seen on coronal images (middle and right). Foci are more distinct with ⁶⁴Cu-DOTATATE than with ⁶⁸Ga-DOTATOC. Spleen shows much higher uptake of ⁶⁸Ga-DOTATOC than of ⁶⁴Cu-DOTATATE.

TABLE 4
Comparison of TBR for ^{64}Cu-DOTATATE and ^{68}Ga-DOTATOC in the 59 Patients with NETs

Region	n*	^{64}Cu-DOTATATE	^{68}Ga-DOTATOC	P‡
Liver	29	5.49 (0.45)	4.60 (0.52)	0.13
Lymph nodes	28	17.90 (1.93)	19.99 (2.25)	0.28
Bones	17	11.98 (2.30)	18.37 (4.11)	0.05
Lung	3	6.10 (1.28))	4.25 (1.41)	0.56
Pancreas	9	9.86 (1.76))	10.34 (2.78)	0.77
Intestines	5	4.92 (1.00))	6.48 (2.13)	0.50

*Number of TBRs with available SUVs for both tumor lesion and normal corresponding tissue in both scans.
†Data are mean followed by SEM in parentheses.
‡Paired-samples test (2-tailed).

the mean TBR for bone was high for both tracers and ⁶⁴Cu-DOTATATE actually did find significantly more lesions than ⁶⁸Ga-DOTATOC.

As a convenient standard workflow, we scanned patients 1 h after injection of ⁶⁴Cu-DOTATATE. This timing was comparable to the routine workflow for the ⁶⁸Ga-labeled somatostatin receptor PET tracers. However, based on the comparison of image quality and the stable SUVs for tumors reported in our previous publication (20), an advantage of ⁶⁴Cu-DOTATATE is the possibility of scanning at any time between 1 and 3 h. Potential better TBRs might be found using a later scanning time, but this possibility cannot be proven in this setup. Finally, ⁶⁴Cu-DOTATATE is produced with a shelf-life of 24 h, logistically circumventing the need for coordination between radiochemistry production and patient arrival.

Our study had some limitations. It cannot be ruled out that the acquisition of a diagnostic CT scan together with the ⁶⁴Cu-DOTATATE PET scan, but not with the ⁶⁸Ga-DOTATOC scan, might have made it easier to detect small lesions using ⁶⁴Cu-DOTATATE. However, since the images were not masked but were compared pairwise, head-to-head (lesion-to-lesion), after the initial lesion detection, the possibility that any lesions would not be found merely because of differences in the CT scan seems unlikely. Furthermore, if we had wanted to assess whether only the change in isotope makes a difference, the fact that we did not compare ⁶⁴Cu-DOTATATE with ⁶⁸Ga-DOTATATE would have been a limitation of our study. However, high sensitivity has been seen using both ⁶⁸Ga-DOTATATE and ⁶⁸Ga-DOTATOC, with no clear documentation of the superiority of one over the other, and therefore it is most likely that it was the difference in radioisotope that caused the differences in our findings. Nevertheless, our main purpose was to see whether ⁶⁴Cu-DOTATATE could compete with the commonly used ⁶⁸Ga-DOTATOC PET tracer.

CONCLUSION

Although patient-based sensitivity was the same for ⁶⁴Cu-DOTATATE and ⁶⁸Ga-DOTATOC in this cohort, ⁶⁴Cu-DOTATATE had a substantially better lesion detection rate in NET patients than did ⁶⁸Ga-DOTATOC. Follow-up revealed that most of the additional

lesions detected by ^{64}Cu-DOTATATE were true-positive. The lower positron range of ^{64}Cu than of ^{68}Ga is probably the main explanation for the better performance. Furthermore, the shelf life of more than 24 h and the flexible scanning window of at least 3 h make ^{64}Cu-DOTATATE attractive for use in clinical routine. Whether detection of more true lesions translates into better patient management and outcome remains to be proven.

DISCLOSURE

ACKNOWLEDGMENTS

REFERENCES

1. Modlin IM, Oberg K, Chung DC, et al. Gastroenteropancreatic neuroendocrine tumours. *Lancet Oncol.* 2008;9:61–72.
2. Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. *J Clin Oncol.* 2008;26:3063–3072.
3. Johnbeck CB, Knigge U, Kjær A. PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature. *Future Oncol.* 2014;10:2259–2277.
4. Hoyer D, Bell GI, Berelowitz M, et al. Classification and nomenclature of somatostatin receptors. *Trends Pharmacol Sci.* 1995;16:86–88.
5. Reubi JC. Somatostatin and other peptide receptors as tools for tumor diagnosis and treatment. *Neuroendocrinology.* 2004;80(suppl 1):51–56.
6. Binderup T, Knigge U, Mellon Mogensen A, Palnaes Hansen C, Kjær A. Quantitative gene expression of somatostatin receptors and noradrenaline transporter underlying scintigraphic results in patients with neuroendocrine tumors. *Neuroendocrinology.* 2008;87:223–232.
7. Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. *Eur J Nucl Med.* 2001;28:836–846.
8. Reubi JC, Schär JC, Waser B, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. *Eur J Nucl Med.* 2000;27:273–282.
9. Krausz Y, Freedman N, Rubinstein R, et al. ^{68}Ga-DOTA-NOC PET/CT imaging of neuroendocrine tumors: comparison with ^{111}In-DTPA-octreotide (OctreoScan®). *Mol Imaging Biol.* 2011;13:583–593.
10. Buchmann I, Henze M, Engelbrecht S, et al. Comparison of ^{68}Ga-DOTATOC PET and ^{111}In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. *Eur J Nucl Med Mol Imaging.* 2007;34:1617–1626.
11. Gabriel M, Decristoforo C, Kendler D, et al. ^{68}Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. *J Nucl Med.* 2007;48:508–518.
12. Srirajaskanthan R, Kayani I, Quigley AM, Soh J, Caplin ME, Bomanji J. The role of ^{68}Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on ^{111}In-DTPA-octreotide scintigraphy. *J Nucl Med.* 2010;51:875–882.
13. Schreiter NF, Brenner W, Nogami M, et al. Cost comparison of ^{111}In-DTPA-octreotide scintigraphy and ^{68}Ga-DOTATOC PET/CT for staging enteropancreatic neuroendocrine tumours. *Eur J Nucl Med Mol Imaging.* 2012;39:72–82.
14. Pfeifer A, Knigge U, Binderup T, et al. ^{64}Cu-DOTATATE PET for neuroendocrine tumors: a prospective head-to-head comparison with ^{111}In-DTPA-octreotide in 112 patients. *J Nucl Med.* 2015;56:847–854.
15. Niederle B, Pape UF, Costa F, et al. ENETS consensus guidelines update for neuroendocrine neoplasm of the jejunum and ileum. *Neuroendocrinology.* 2016;103: in press.
16. Falconi M, Eriksson B, Kaltsas G, et al. ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors. *Neuroendocrinology.* 2016;103:153–171.
17. Caplin ME, Baudin E, Ferolla P, et al. Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. *Ann Oncol.* 2015;26:1604–1620.
18. Tabaksblat EM, Langer SW, Knigge U, et al. Diagnosis and treatment of bronchopulmonary neuroendocrine tumours: state of the art. *Acta Oncol.* 2016;55:3–14.
19. Garcia-Carbonero R, Sorbye H, Baudin E, et al. ENETS consensus guidelines for high-grade gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomas. *Neuroendocrinology.* 2016;103:186–194.
20. Pfeifer A, Knigge U, Mortensen J, et al. Clinical PET of neuroendocrine tumors using ^{64}Cu-DOTATATE: first-in-humans study. *J Nucl Med.* 2012;53:1207–1215.
21. Treglia G, Castaldi P, Rindi G, Giordano A, Rufini V. Diagnostic performance of gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis. *Endocrine.* 2012;42:80–87.
22. Poeppel TD, Binse I, Petersenn S, et al. ^{68}Ga-DOTATOC versus ^{68}Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors. *J Nucl Med.* 2011;52:1864–1870.
23. Kabasakal L, Demirci E, Ocak M, et al. Comparison of ^{68}Ga-DOTATATE and ^{68}Ga-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours. *Eur J Nucl Med Mol Imaging.* 2012;39:1271–1277.
24. Demirci E, Ocak M, Kabasakal L, Araman A, Ozsoy Y, Kanmaz B. Comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-LAN PET/CT imaging in the same patient group with neuroendocrine tumours. *Nucl Med Commun.* 2013;34: 727–732.
25. Poeppel TD, Binse I, Petersenn S, et al. Differential uptake of ^{68}Ga-DOTATOC and ^{68}Ga-DOTATATE in PET/CT of gastroenteropancreatic neuroendocrine tumors. *Recent Results Cancer Res.* 2013;194:353–371.
26. Putzer D, Kroiss A, Waitz D, et al. Somatostatin receptor PET in neuroendocrine tumours: ^{68}Ga-DOTA[0],Tyr[3]-octreotide versus ^{68}Ga-DOTA[0]-lanreotide. *Eur J Nucl Med Mol Imaging.* 2013;40:364–372.
27. Wild D, Bomanji JB, Benkert P, et al. Comparison of ^{68}Ga-DOTANOC and ^{68}Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors. *J Nucl Med.* 2013;54:364–372.
28. Yang J, Kan Y, Ge BH, Yuan L, Li C, Zhao W. Diagnostic role of gallium-68 DOTATOC and gallium-68 DOTATATE PET in patients with neuroendocrine tumors: a meta-analysis. *Acta Radiol.* 2014;55:389–398.
29. Hartmann H, Zöphel K, Freudenberg R, et al. Radiation exposure of patients during ^{68}Ga-DOTATOC PET/CT examinations [in German]. *Nuklearmedizin.* 2009;48:201–207.
30. Kwekkeboom DJ, Kooij PP, Bakker WH, Mäcke HR, Krenning EP. Comparison of ^{111}In-DOTA-Tyr[3]-octreotide and ^{111}In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake. *J Nucl Med.* 1999;40:762–767.